BRAIN and NERVE－神経研究の進歩74巻8号

2022年08月発行

特集 迷走神経の不思議

パーキンソン病におけるαシヌクレイン異常凝集体は迷走神経を介して上行する

著者： 大野欽司¹ 平山正昭²

所属機関： ¹名古屋大学大学院医学系研究科神経遺伝情報学 ²名古屋大学大学院医学系研究科医療技術学

ページ範囲：P.979 - P.984

文献概要

パーキンソン病（Parkinson's disease：PD）の中脳黒質神経細胞に蓄積するαシヌクレイン異常凝集体（レビー小体）はプリオンの性質を有する。αシヌクレイン異常蓄積は，PDの腸管神経叢に高率に認められ，剖検脳の検討では延髄から中脳黒質に上行する。事実，迷走神経全切除術はPD発症率を半減する。加えてPDでは短鎖脂肪酸（SCFA）産生菌が低下する。SCFAによる迷走神経刺激がPDにおいて低下することもPD病態の進行を促進する可能性が示唆される。

参考文献

1）Pringsheim T, Jette N, Frolkis A, Steeves TD: The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 29: 1583-1590, 2014

2）Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, et al: Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249 Suppl 3: III/1-5, 2002

3）Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, et al: Prion-like spreading of pathological α-synuclein in brain. Brain 136: 1128-1138, 2013

4）Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, et al: Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 112: E5308-5317, 2015

5）Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, et al: Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord 29: 999-1009, 2014

6）Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, et al: Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 27: 709-715, 2012

7）Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH: Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 27: 716-719, 2012

8）Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, et al: Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 78: 522-529, 2015

9）Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, et al: Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology 88: 1996-2002, 2017

10）Breid S, Bernis ME, Babila JT, Garza MC, Wille H, et al: Neuroinvasion of α-synuclein prionoids after intraperitoneal and intraglossal inoculation. J Virol 90: 9182-9193, 2016

11）Uemura N, Yagi H, Uemura MT, Hatanaka Y, Yamakado H, et al: Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol Neurodegener 13: 21, 2018［doi: 10.1186/s13024-018-0257-5］

12）Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, et al: Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2: 898, 2012［doi: 10.1038/srep00898］

13）Drokhlyansky E, Smillie CS, Van Wittenberghe N, Ericsson M, Griffin GK, et al: The human and mouse enteric nervous system at single-cell resolution. Cell 182: 1606-1622, 2020

14）Han W, Tellez LA, Perkins MH, Perez IO, Qu T, et al: A neural circuit for gut-induced reward. Cell 175: 665-678, 2018

15）Kaelberer MM, Buchanan KL, Klein ME, Barth BB, Montoya MM, et al: A gut-brain neural circuit for nutrient sensory transduction. Science 361: eaat5236, 2018［doi: 10.1126/science.aat5236］

16）Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, et al: Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLOS ONE 6: e28032, 2011［doi: 10.1371/journal.pone.0028032］

17）Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, et al: Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. PLOS ONE 10: e0142164, 2015［doi: 10.1371/journal.pone.0142164］

18）Qin L, Wu X, Block ML, Liu Y, Breese GR, et al: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462, 2007

19）Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, et al: Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167: 1469-1480, 2016

20）Hirayama M, Ohno K: Parkinson's disease and gut microbiota. Ann Nutr Metab 77 Suppl 2: 28-35, 2021

21）Nishiwaki H, Ito M, Ishida T, Hamaguchi T, Maeda T, et al: Meta-analysis of gut dysbiosis in Parkinson's disease. Mov Disord 35: 1626-1635, 2020

22）Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, et al: Pesticide exposure and risk for Parkinson's disease. Ann Neurol 60: 197-203, 2006

23）Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, et al: Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut 46: 218-224, 2000

24）Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, et al: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 446-450, 2013

25）Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, et al: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341: 569-573, 2013

26）Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, et al: Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 390: 1664-1675, 2017

27）Yun SP, Kam TI, Panicker N, Kim S, Oh Y, et al: Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med 24: 931-938, 2018

28）Nishiwaki H, Ito M, Hamaguchi T, Maeda T, Kashihara K, et al: Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson's disease. NPJ Parkinsons Dis 8: 65, 2022［doi.org/10.1038/s41531-022-00328-5］